2026 ICD-10-CM Diagnosis Code T80.810AExtravasation of vesicant antineoplastic chemotherapy, initial encounter
ICD-10-CM Codes›S00–T88›T80-T88›T80
- Billable — Valid for Submission
- CC — Complication or Comorbidity
- 7th Character A — Initial Encounter
- Chronic Condition
T80.810A is a billable ICD-10-CM diagnosis code for extravasation of vesicant antineoplastic chemotherapy, initial encounter. The 7th character A marks it as an initial encounter code, used while the patient is receiving active treatment. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026) and groups to MS-DRG 314 through 316, 791, 793. As a secondary diagnosis, it counts as a complication or comorbidity (CC) and moves an inpatient stay to a higher severity level within its MS-DRG family. It does not count, however, when the principal diagnosis is one of 4 closely related codes. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Complication of other surgical or medical care, injury, initial encounter; and Conditions due to neoplasm or the treatment of neoplasm.
Code Identity
Code Classification
Coding GuidelinesGuidance
The appropriate 7th character is to be added to each code from block Complications following infusion, transfusion and therapeutic injection (T80). Use the following options for the applicable episode of care:
- A - initial encounter
- D - subsequent encounter
- S - sequela
Source: ICD-10-CM Official Guidelines for Coding and Reporting, FY 2026, published by CMS and the National Center for Health Statistics.
Clinical ClassificationClinical
AHRQ’s CCSR groups this code into broader clinical categories.
Convert T80.810A to ICD-9-CMHistory
The closest ICD-9-CM equivalents under the General Equivalence Mappings.
Code HistoryHistory
Questions About T80.810AOverview
Is T80.810A (Extravasation of vesicant antineoplastic chemotherapy) a billable code?
Yes. This is a billable ICD-10-CM code, specific enough to report extravasation of vesicant antineoplastic chemotherapy, initial encounter on HIPAA-covered claims from October 1, 2025 through September 30, 2026.
What does the 7th character A in T80.810A mean?
The final character A marks the initial encounter: use it while the patient is receiving active treatment for extravasation of vesicant antineoplastic chemotherapy, such as an emergency visit or first evaluation.
What MS-DRG does T80.810A group to?
When extravasation of vesicant antineoplastic chemotherapy, initial encounter is the principal diagnosis on an inpatient stay, it groups to MS-DRG 314, 315, 316, 791, 793, with relative weights from 0.6821 to 4.1696 depending on complications. Higher weights mean higher Medicare reimbursement.
Is T80.810A a CC or MCC?
CMS lists T80.810A as a CC (complication or comorbidity) for FY 2026. Reported as a secondary diagnosis, it moves the inpatient stay to a higher-weighted DRG within its severity family. It does not count when the principal diagnosis is one of the 4 closely related codes in its exclusion list.
What is the ICD-9 equivalent of T80.810A?
Under the General Equivalence Mappings, extravasation of vesicant antineoplastic chemotherapy, initial encounter converts to ICD-9-CM 999.81 (extravstn vesicant chemo). The mapping is approximate, so confirm the match fits the documentation.
